The FDA has updated the labeling for Camzyos to reduce echocardiogram monitoring requirements for patients in the maintenance phase and contraindications.

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Based in Tarrytown, New York, the company’s products include EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, and Kevzara. More Top Stocks Daily: Go behind Wall Street’s hottest headlines with ...

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier ...

The FDA has approved a prefilled syringe formulation of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) that allows patients to self-inject the medication.

“It is vital to address the cause of pain with a doctor, read the package inserts, heed warnings and ask the right questions of your healthcare practitioner or pharmacist before taking new ...

SPECIALLY DESIGNED FOR SPORTS LOVERS: This arch support insert is designed for providing excellent protection and support for sports lovers. CORALMANOR womens arch support inserts can effectively ...

TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has ...

PLANTAR FASCIITIS RELIEF SHOE INSERT: With the widest and deepest heel cradle design, the heel and feet high quality adaption, FeelLife protects your heel during the heavy impact during running or ...